CCR1 and malignant colon neoplasm: Additionally, studies have reported that inhibiting CCR1 with the receptor antagonist BL5923 suppresses the recruitment of immature myeloid cells, leading to a reduction in metastatic colon cancer and a significant prolongation of survival in mice with colon cancer liver metastasis (50).